ライフサイエンスコーパス: demyelinating disease

1 rsistence associated with an immune-mediated demyelinating disease.

2 nent role in the development of TMEV-induced demyelinating disease.

3 t leukodystrophy (ADLD), a fatal adult onset demyelinating disease.

4 accelerating myelin clearance and improving demyelinating disease.

5 susceptibility of mice to the development of demyelinating disease.

6 icrocystic macular edema is not specific for demyelinating disease.

7 gression in a secondary progressive model of demyelinating disease.

8 ts the potential for cell-based treatment of demyelinating disease.

9 ovement disorders, psychiatric features, and demyelinating disease.

10 cephalitis, followed by a nonlethal, chronic demyelinating disease.

11 y chronic hemolysis and relapsing peripheral demyelinating disease.

12 potential therapeutic target for autoimmune demyelinating disease.

13 lding a comprehensive model for TMEV-induced demyelinating disease.

14 l role in the pathogenicity of virus-induced demyelinating disease.

15 ion against the development of virus-induced demyelinating disease.

16 nic and regulatory roles these cells play in demyelinating disease.

17 t into the mechanisms promoting inflammatory demyelinating disease.

18 al infection, leading to the pathogenesis of demyelinating disease.

19 undermine vitamin D3-mediated inhibition of demyelinating disease.

20 nonuclear cells (PBMCs) of 228 subjects with demyelinating disease.

21 T cell response offers protection from this demyelinating disease.

22 n of viral proteins during the late stage of demyelinating disease.

23 t to both viral persistence and TMEV-induced demyelinating disease.

24 model for studies of viral encephalitis and demyelinating disease.

25 ctive in experimental models of inflammatory demyelinating disease.

26 cells play in development and progression of demyelinating disease.

27 ult pathway in the CNS in nonimmune-mediated demyelinating disease.

28 specific CD4(+) T cell responses and reduced demyelinating disease.

29 tiate oligodendrocyte survival in autoimmune demyelinating disease.

30 the CNS which contributes to development of demyelinating disease.

31 he first confirmed antigenic target in human demyelinating disease.

32 al therapeutical avenue for lesion repair in demyelinating disease.

33 n HLA class II molecules in inflammatory and demyelinating disease.

34 ction and induce the pathogenesis of chronic demyelinating disease.

35 istance or susceptibility to virally induced demyelinating disease.

36 ple sclerosis (MS) is a human CNS autoimmune demyelinating disease.

37 d progression of the autoimmune response and demyelinating disease.

38 sponses and contribute to the development of demyelinating disease.

39 associated with an inflammatory white matter demyelinating disease.

40 f antiserum to IFN-beta led to a more severe demyelinating disease.

41 lerosis (MS) is a heterogeneous inflammatory demyelinating disease.

42 ultifocal leukoencephalopathy (PML), a fatal demyelinating disease.

43 al leukoencephalopathy (PML), a rare, fatal, demyelinating disease.

44 ler's murine encephalomyelitis virus-induced demyelinating disease.

45 ler's murine encephalomyelitis virus-induced demyelinating disease.

46 lammatory and proliferative genes to promote demyelinating disease.

47 ENT Multiple sclerosis is a severe, chronic, demyelinating disease.

48 ation in OPCs, contributing to Th17-mediated demyelinating disease.

49 ying pathogenesis in autoimmune inflammatory demyelinating diseases.

50 e development of multiple sclerosis or other demyelinating diseases.

51 sclerosis and a composite end point of other demyelinating diseases.

52 ral nervous system inflammatory and acquired demyelinating diseases.

53 nt diagnoses of multiple sclerosis and other demyelinating diseases.

54 al relationship between qHPV vaccination and demyelinating diseases.

55 ferentiation in multiple sclerosis and other demyelinating diseases.

56 development of multiple sclerosis and other demyelinating diseases.

57 aluate their roles and clinical relevance in demyelinating diseases.

58 a key target for enhancing myelin repair in demyelinating diseases.

59 A class II genes in chronic inflammatory and demyelinating diseases.

60 e for oligodendrogenesis and remyelinaton in demyelinating diseases.

61 PCs) offer a promising approach for treating demyelinating diseases.

62 and adhesion and has direct implications for demyelinating diseases.

63 may provide new avenues in the treatment of demyelinating diseases.

64 ual function and may be a general feature of demyelinating diseases.

65 humans, may find further therapeutic use in demyelinating diseases.

66 ole of the innate immune system in mediating demyelinating diseases.

67 esoxime could be useful for the treatment of demyelinating diseases.

68 nesis of central nervous system inflammatory demyelinating diseases.

69 rovide an effective therapeutic approach for demyelinating diseases.

70 JME may shed new light on MS and other human demyelinating diseases.

71 yelination, which has broad implications for demyelinating diseases.

72 ernodal axon in paraneoplastic syndromes and demyelinating diseases.

73 nd development of regenerative therapies for demyelinating diseases.

74 for therapeutic targeting of LSDs and other demyelinating diseases.

75 c proteins in myelin with relevance to human demyelinating diseases.

76 t enhance remyelination in patients with CNS demyelinating diseases.

77 e significant potential for treating chronic demyelinating diseases.

78 for enhancing remyelination in patients with demyelinating diseases.

79 MAD (pSMAD) 1/5/8 in lesions of MS and other demyelinating diseases.

80 development in multiple sclerosis and other demyelinating diseases.

81 his pool of progenitors to replace myelin in demyelinating diseases.

82 mportant role in the pathogenesis underlying demyelinating diseases.

83 xonal degeneration that occurs in peripheral demyelinating diseases.

84 ent neuron-supportive programme in inherited demyelinating disease?

85 ecific CD8(+) T cells in the pathogenesis of demyelinating disease, a single amino acid substitution

86 6 transgene (IL-6 Tg) develop a TMEV-induced demyelinating disease accompanied by an increase in vira

87 r the development of Tob1 as a biomarker for demyelinating disease activity.

88 disorders including traumatic brain injury, demyelinating disease, Alzheimer's disease (AD), and Par

89 ive lesions are an uncommon manifestation of demyelinating disease and can pose a diagnostic challeng

90 In multiple sclerosis (MS), an autoimmune demyelinating disease and common cause of neurodegenerat

91 r vitamin D in the regenerative component of demyelinating disease and identify a new target for remy

92 hrough the alternative complement cascade in demyelinating disease and identify a strategy to prevent

93 ation abnormalities seen in association with demyelinating disease and optic neuritis, although evide

94 motes recovery from preexisting inflammatory demyelinating disease and suggest that this protection i

95 neficial both for enhancing remyelination in demyelinating diseases and for increasing neural plastic

96 the potential for enhanced remyelination in demyelinating diseases and increased neural plasticity i

97 target, as well as an imaging biomarker, for demyelinating diseases and potentially for other disease

98 ors may prove safe and effective in treating demyelinating diseases and potentially other autoimmune

99 hat implicate glial gap junction proteins in demyelinating diseases and the therapeutic potential of

100 hemorrhage, intracranial hemorrhage, spine, demyelinating disease, and epileptic patients.

101 design of neuroprotective strategies for CNS demyelinating disease, and our model identifies the spik

102 hich the olfactory system is affected in CNS demyelinating diseases, and raises intriguing questions

103 ivation and the pathogenesis of TMEV-induced demyelinating disease are largely unknown.

104 CNS repair following lesions associated with demyelinating diseases are still unresolved.

105 n A59, causes acute encephalitis and chronic demyelinating disease as well as hepatitis in mice.

106 ted in the pathogenesis of neuroinflammatory demyelinating diseases as well as enhancement of the mig

107 Multiple sclerosis is a demyelinating disease associated with an inflammatory im

108 irmed that NFM was not a critical Ag driving demyelinating disease because NFM18-30-specific T cells

109 d cell leukodystrophy (GLD), a genetic fatal demyelinating disease, because its rapidly progressive d

110 unogenic in C57BL/6 mice but fails to induce demyelinating disease by polyclonal T cells despite havi

111 dy definitively demonstrates that autoimmune demyelinating disease can be driven by distinct Th-polar

112 ultifocal leukoencephalopathy (PML), a fatal demyelinating disease caused by JC virus (JCV) infection

113 id-cell leukodystrophy (GLD) is an inherited demyelinating disease caused by the deficiency of the ly

114 al leukoencephalopathy (PML) is a lethal CNS demyelinating disease caused by the human neurotropic po

115 Multiple sclerosis (MS) is a human demyelinating disease characterized by multifocal region

116 Because functional restoration in demyelinating diseases critically depends on the success

117 te ratio, 0.90 [95% CI, 0.70-1.15]) or other demyelinating diseases (crude incidence rates, 7.54 even

118 hat is frequently used to study inflammatory demyelinating diseases, due to increased resistance of t

119 In multiple sclerosis, an inflammatory demyelinating disease, endogenous remyelination does occ

120 nterleukin-6 (IL-6) levels contribute to the demyelinating disease found in chronically infected SJL/

121 In the 2.3% with demyelinating disease, gabapentin was the most likely se

122 MHV CNS infection and developed progressive demyelinating disease, germline IgM produced in activati

123 Theiler's virus-induced demyelinating disease has been extensively investigated

124 Treatment against demyelinating diseases has been elusive, partially becau

125 ed that myelitis occurring in the idiopathic demyelinating diseases (i.e., multiple sclerosis versus

126 spectrum disorders (NMOSD) are inflammatory demyelinating diseases (IDD) with a specific biomarker,

127 D8 T cells results in an attenuated clinical demyelinating disease in C57BL/6 mice with immunization-

128 sive multifocal leukoencephalopathy (PML), a demyelinating disease in humans.

129 that has been linked to JME, an inflammatory demyelinating disease in Japanese macaques that mimics m

130 As such, TMEV-induced demyelinating disease in mice provides a highly relevant

131 yelitis virus (TMEV)-induced immune-mediated demyelinating disease in susceptible mouse strains has b

132 itis virus (TMEV) induces an immune-mediated demyelinating disease in susceptible mouse strains such

133 yelitis virus (TMEV) induces immune-mediated demyelinating disease in susceptible SJL/J mice but not

134 yelin can be replaced after injury or during demyelinating diseases in a regenerative process called

135 is result in the impairment of recovery from demyelinating diseases in the adult.

136 al prerequisite for developing therapies for demyelinating diseases in the PNS.

137 s for the application of LRRK2 inhibitors in demyelinating diseases in which oligodendrocyte cell-dea

138 cells against VP3(159-166), did not develop demyelinating disease, in contrast to wild-type virus or

139 dence ratio, 1.05 [95% CI, 0.79-1.38]; other demyelinating diseases: incidence ratio, 1.14 [95% CI, 0

140 risk factor for central nervous system (CNS) demyelinating diseases including multiple sclerosis (MS)

141 ar endothelium is a key step in inflammatory demyelinating diseases including multiple sclerosis (MS)

142 In demyelinating diseases including multiple sclerosis (MS)

143 Myelin loss occurring in demyelinating diseases, including multiple sclerosis, is

144 cations of resveratrol in human inflammatory demyelinating diseases, including multiple sclerosis.

145 on with these epitopes on the development of demyelinating disease indicated that capsid-specific CD4

146 urine encephalomyelitis virus (TMEV)-induced demyelinating disease is a relevant mouse model for the

147 Progression of demyelinating diseases is caused by an imbalance of two

148 Multiple sclerosis (MS), an inflammatory demyelinating disease, is a major cause of neurological

149 patient who died from a rapidly progressing demyelinating disease known as progressive multifocal le

150 t that oral GlcNAc may be neuroprotective in demyelinating diseases like MS.

151 portant role in cognitive development and in demyelinating diseases like multiple sclerosis (MS), whe

152 failure is a major goal of new therapies for demyelinating diseases like multiple sclerosis.

153 ant factor in determining disease outcome in demyelinating diseases like multiple sclerosis.

154 SIRT1 reduces neuronal loss in this chronic demyelinating disease model and that this is associated

155 differentiation and induce remyelination in demyelinating disease models.

156 in the pathogenesis of the human autoimmune demyelinating disease multiple sclerosis (MS) and in its

157 The demyelinating disease multiple sclerosis (MS) has an ear

158 Current therapies for the autoimmune demyelinating disease multiple sclerosis (MS) target inf

159 utes to the pathogenesis of the inflammatory demyelinating disease multiple sclerosis (MS).

160 myelin repair in animal models of the human demyelinating disease multiple sclerosis (MS).

161 PCs), thereby impeding remyelination, in the demyelinating disease multiple sclerosis (MS).

162 functional impairment that characterizes the demyelinating disease multiple sclerosis (MS).

163 lination in a preclinical model of the human demyelinating disease multiple sclerosis (MS).IMPORTANCE

164 of permanent disability in the inflammatory demyelinating disease multiple sclerosis, but no therapi

165 gical disability in individuals with the CNS demyelinating disease multiple sclerosis.

166 cephalomyelitis, a rodent model of the human demyelinating disease multiple sclerosis.

167 In the most prominent demyelinating disease, multiple sclerosis, the regenerat

168 yelination similar in pathology to the human demyelinating disease, multiple sclerosis.

169 spinal cord injury, peripheral nerve injury, demyelinating disease, neuromuscular disorders, and seiz

170 The neuroinflammatory demyelinating disease neuromyelitis optica is marked by

171 autoantibody found in the neuroinflammatory demyelinating disease neuromyelitis optica.

172 euromyelitis optica (NMO) is an inflammatory demyelinating disease of spinal cord and optic nerve cau

173 ifocal leukoencephalopathy (PML) is a severe demyelinating disease of the brain caused by JC virus (J

174 sive multifocal leukoencephalopathy (PML), a demyelinating disease of the brain caused by the polyoma

175 lation and is the causative agent of a fatal demyelinating disease of the central nervous system (CNS

176 MS is a chronic idiopathic inflammatory demyelinating disease of the central nervous system (CNS

177 ple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS

178 Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system (CNS

179 ple sclerosis (MS) is a chronic inflammatory demyelinating disease of the central nervous system (CNS

180 Multiple sclerosis is an inflammatory demyelinating disease of the central nervous system (CNS

181 NMOSD is a recently defined demyelinating disease of the central nervous system (CNS

182 Multiple sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS

183 euromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system asso

184 Neuromyelitis optica is an inflammatory demyelinating disease of the central nervous system asso

185 euromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system caus

186 gressive multifocal leukoencephalopathy is a demyelinating disease of the central nervous system caus

187 euromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system caus

188 euromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system in w

189 Multiple sclerosis (MS) is a common demyelinating disease of the central nervous system medi

190 Multiple sclerosis (MS) is a demyelinating disease of the central nervous system that

191 Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the central nervous system that

192 ve multifocal leukoencephalopathy (PML) is a demyelinating disease of the central nervous system that

193 Multiple sclerosis (MS) is a chronic demyelinating disease of the central nervous system trad

194 h multiple sclerosis, a chronic inflammatory demyelinating disease of the central nervous system with

195 Multiple sclerosis (MS) is a demyelinating disease of the central nervous system, lea

196 onsidered the prototype for an inflammatory, demyelinating disease of the central nervous system, mod

197 autoimmune, inflammatory, neurodegenerative, demyelinating disease of the central nervous system, pre

198 sclerosis (MS) (n=43,879), an inflammatory, demyelinating disease of the central nervous system.

199 sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the central nervous system.

200 euromyelitis optica (NMO) is an inflammatory demyelinating disease of the central nervous system.

201 Multiple sclerosis is a chronic inflammatory demyelinating disease of the central nervous system.

202 ple sclerosis (MS) is the major inflammatory demyelinating disease of the central nervous system.

203 iple sclerosis (MS) is the most common human demyelinating disease of the central nervous system.

204 expression of viral proteins, and induces a demyelinating disease of the central nervous system.

205 ple sclerosis (MS) is known as an autoimmune demyelinating disease of the central nervous system.

206 leukoencephalopathy (PML) is an often-fatal demyelinating disease of the central nervous system.

207 Centres managing patients with demyelinating disease of the CNS across Australia and Ne

208 euromyelitis optica (NMO) is an inflammatory demyelinating disease of the CNS and affects women of ch

209 Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS and remyelination in MS

210 Multiple sclerosis (MS) is a demyelinating disease of the CNS characterized by inflam

211 lls, and its role in autoimmune inflammatory demyelinating disease of the CNS has not been studied.

212 Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the CNS mediated by self-reacti

213 Multiple sclerosis is an inflammatory, demyelinating disease of the CNS of presumed autoimmune

214 nd multiple sclerosis (MS), an inflammatory, demyelinating disease of the CNS of unknown etiology.

215 Multiple sclerosis (MS) is an autoimmune demyelinating disease of the CNS resulting from a progre

216 sclerosis (MS) is an autoimmune inflammatory demyelinating disease of the CNS that causes disability

217 ultiple sclerosis (MS) is an immune-mediated demyelinating disease of the CNS that has been linked wi

218 ncephalomyelitis is a CD4(+) T cell-mediated demyelinating disease of the CNS that serves as a model

219 AE) is a CD4(+) T cell-mediated inflammatory demyelinating disease of the CNS that serves as a model

220 ultiple sclerosis (MS) is an immune-mediated demyelinating disease of the CNS, and CD8 T cells are th

221 Multiple sclerosis is a sexually dimorphic, demyelinating disease of the CNS, and experimental aller

222 Multiple sclerosis is a chronic, demyelinating disease of the CNS.

223 of multiple sclerosis (MS), an inflammatory demyelinating disease of the CNS.

224 Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the CNS.

225 Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS.

226 e sclerosis (MS), a chronic inflammatory and demyelinating disease of the CNS.

227 T Multiple sclerosis (MS) is an inflammatory demyelinating disease of the CNS.

228 Multiple sclerosis (MS) is a chronic demyelinating disease of the CNS.

229 tiple sclerosis (MS) is a neuroinflammatory, demyelinating disease of the CNS.

230 Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the human central nervous syste

231 ultiple Sclerosis (MS) is an immune-mediated demyelinating disease of the human central nervous syste

232 MS) is a spontaneous, acquired, inflammatory demyelinating disease of the human CNS.

233 ve multifocal leukoencephalopathy (PML) is a demyelinating disease of the white matter of the human b

234 m the traditional view of a T cell-mediated, demyelinating disease of the white matter to include a b

235 w diagnostic markers in these two autoimmune demyelinating diseases of the central nervous system.

236 therapeutic modulation of ERK1/2 activity in demyelinating disease or peripheral neuropathies must be

237 We propose that the inflammatory demyelinating disease process in early multiple sclerosi

238 tion and is the causative agent of the fatal demyelinating disease progressive multifocal leukoenceph

239 ty of the population and can cause the fatal demyelinating disease progressive multifocal leukoenceph

240 compromised individuals results in the fatal demyelinating disease progressive multifocal leukoenceph

241 -specific virus, causes the aggressive brain-demyelinating disease progressive multifocal leukoenceph

242 virus (JCPyV) causes the rapidly progressing demyelinating disease progressive multifocal leukoenceph

243 mavirus and the causative agent of the fatal demyelinating disease progressive multifocal leukoenceph

244 ression, JCV can infect the brain, causing a demyelinating disease, progressive multifocal leukoencep

245 tral nervous system and chronic inflammatory demyelinating disease, providing an experimental animal

246 finding may have important implications for demyelinating diseases, psychiatric disorders, and cogni

247 DA-induced demyelinating disease serves as a model of human multipl

248 urine encephalomyelitis virus (TMEV)-induced demyelinating disease serves as a relevant mouse model f

249 composition and low MBP concentration, as in demyelinating disease, show structural instabilities and

250 inflammation and promote myelin recovery in demyelinating diseases.SIGNIFICANCE STATEMENT Reducing v

251 ising strategies to advance the treatment of demyelinating diseases.SIGNIFICANCE STATEMENT The benefi

252 e multicentre prospective Canadian Pediatric Demyelinating Disease Study (CPDDS).

253 reported in patients that recover from acute demyelinating diseases such as Guillain-Barre syndrome.

254 ss of visual function frequently accompanies demyelinating diseases such as multiple sclerosis (MS) a

255 tions including central nervous system (CNS) demyelinating diseases such as multiple sclerosis (MS) a

256 elin regeneration can occur spontaneously in demyelinating diseases such as multiple sclerosis (MS).

257 erapy in the CNS, particularly for long-term demyelinating diseases such as multiple sclerosis (MS).

258 therapeutic approaches for the treatment of demyelinating diseases such as multiple sclerosis (MS).S

259 ul in many neurological disorders, including demyelinating diseases such as multiple sclerosis and th

260 Demyelinating diseases such as multiple sclerosis are ch

261 nstitute clinically debilitating sequelae in demyelinating diseases such as multiple sclerosis, but t

262 axons, associated with traumatic injury and demyelinating diseases such as multiple sclerosis, cause

263 In demyelinating diseases such as multiple sclerosis, disru

264 ng rates underlies degenerative processes in demyelinating diseases such as multiple sclerosis.

265 approach for potential treatment of chronic demyelinating diseases such as multiple sclerosis.

266 s can be therapeutically enhanced in chronic demyelinating diseases such as multiple sclerosis.

267 on's, and amyotrophic lateral sclerosis, and demyelinating diseases such as multiple sclerosis.

268 lopment and crucial for myelin repair in CNS demyelinating diseases such as multiple sclerosis.

269 loping new therapeutic tools to intervene in demyelinating diseases such as multiple sclerosis.

270 lination underlies the progressive nature of demyelinating diseases such as multiple sclerosis.

271 o ameliorate the devastating consequences of demyelinating diseases such as multiple sclerosis.

272 hat Shp2 is a relevant therapeutic target in demyelinating diseases such as multiple sclerosis.SIGNIF

273 target of axonal protection in inflammatory demyelinating diseases, such as multiple sclerosis and p

274 Demyelinating diseases, such as multiple sclerosis, are

275 BP is an abundant myelin protein involved in demyelinating diseases, such as multiple sclerosis.

276 ssive multifocal leukoencephalopathy, a rare demyelinating disease that occurs in the setting of prol

277 are, typically fatal, central nervous system demyelinating disease that results from reactivation of

278 In glaucoma, which is not considered a demyelinating disease, the observed increase in radial d

279 Because, in demyelinating diseases, the myelin formed during remyeli

280 ically useful as immunomodulatory agents for demyelinating diseases through a novel mechanism involvi

281 Although TMEV-induced demyelinating disease (TMEV-IDD) is thought to be immune

282 ler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD), a well-established ani

283 ler's murine encephalomyelitis virus-induced demyelinating disease (TMEV-IDD).

284 the pathogenesis of Theiler's virus-induced demyelinating disease (TMEV-IDD).

285 ve multifocal leukoencephalopathy (PML) is a demyelinating disease triggered by infection with the hu

286 rimate model of MS, and two rodent models of demyelinating disease, we investigated synapse changes i

287 otton rat Sigmodon hispidus For a long time, demyelinating diseases were considered to be autoimmune

288 iple sclerosis cases and 3300 cases of other demyelinating diseases were identified, of which 73 and

289 peutic enhancement of remyelination in those demyelinating diseases where GPR17 is highly expressed,

290 sceptible mice results in an immune-mediated demyelinating disease which is considered a relevant vir

291 ven by excessive microglial pruning early in demyelinating disease, which can be rescued by inhibitin

292 with TMEV induces the development of chronic demyelinating disease, which is considered a relevant in

293 specific CD4(+) T cell responses and reduced demyelinating disease, which was associated with decreas

294 onfirmed central nervous system inflammatory demyelinating disease who had undergone either diagnosti

295 s virus (JHMV) results in an immune-mediated demyelinating disease with clinical and histologic simil

296 TMEV-infected mice develop a demyelinating disease with clinical symptoms beginning a

297 Multiple sclerosis (MS) is a multifocal demyelinating disease with progressive neurodegeneration

298 e sclerosis (MS) are considered inflammatory demyelinating diseases with distinguishing pathological

299 titis virus (JHMV) develop acute and chronic demyelinating diseases with histopathological similariti

300 mmune cell infiltration in neuroinflammatory demyelinating diseases; yet, the causal link between inf